

# **LANTERN PHARMA INC.**

Reported by  
**BIOS FUND I QP, LP**

## **FORM 144**

(Report of proposed sale of securities)

Filed 04/26/24

Address	1920 MCKINNEY AVENUE 7TH FLOOR DALLAS, TX, 75201
Telephone	972-277-1136
CIK	0001763950
Symbol	LTRN
Fiscal Year	12/31

144: Issuer Information

Name of Issuer	Lantern Pharma Inc.
SEC File Number	001-39318
Address of Issuer	1920 MCKINNEY AVENUE, 7TH FLOOR DALLAS TEXAS 75201
Phone	972-277-1136
Name of Person for Whose Account the Securities are To Be Sold	Bios Fund I QP, LP

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer	1. Affiliate (10% owner)
------------------------	--------------------------

144: Securities Information

Record	Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
#1	Common Stock	Sanders Morris Harris 5950 Sherry Lane, Ste 470 Dallas TEXAS 75225	217,553	\$1,161,733.02	10,741,324	04/29/2024	NASDAQ

144: Securities To Be Sold

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

Record	Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift ?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
#1	Common Stock	06/15/2020	Conversion of Shares in IPO	Issuer	<input type="checkbox"/>	—	329,903	06/15/2020	Conversion

\* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

144: Securities Sold During The Past 3 Months

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

Record	Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
#1	Bios Fund II QP, LP 1751 River Run, Suite 400 Fort Worth TEXAS 76107	Common Stock	02/27/2024	34,731	\$152,816.40
#2	Bios Fund II QP, LP 1751 River Run, Suite 400 Fort Worth TEXAS 76107	Common Stock	02/28/2024	51,608	\$250,298.80
#3	Bios Fund II QP, LP 1751 River Run, Suite 400 Fort Worth TEXAS 76107	Common Stock	02/29/2024	13,686	\$66,650.82
#4	Bios Fund II NT, LP 1751 River Run, Suite 400 Fort Worth TEXAS 76107	Common Stock	02/27/2024	4,649	\$20,455.60
#5	Bios Fund II NT, LP 1751 River Run, Suite 400 Fort Worth TEXAS 76107	Common Stock	02/28/2024	6,909	\$33,508.65
#6	Bios Fund II NT, LP 1751 River Run, Suite 400 Fort Worth TEXAS 76107	Common Stock	02/29/2024	1,832	\$8,921.84
#7	Bios Fund II, LP 1751 River Run, Suite 400 Fort Worth TEXAS 76107	Common Stock	02/27/2024	10,620	\$46,728.00
#8	Bios Fund II, LP 1751 River Run, Suite 400 Fort Worth TEXAS 76107	Common Stock	02/28/2024	15,780	\$76,533.00
#9	Bios Fund II, LP 1751 River Run, Suite 400 Fort Worth TEXAS 76107	Common Stock	02/29/2024	4,185	\$20,380.95

## 144: Remarks and Signature

Remarks

Date of Notice

04/26/2024

### ***ATTENTION:***

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

/s/ Daniel Schwarz

***ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)***